nav emailalert searchbtn searchbox tablepage yinyongbenwen piczone journalimg journalInfo journalinfonormal searchdiv searchzone qikanlogo popupnotification paper paperNew
2026, 02, v.42 2-9
茵陈五苓散调控AMPK/PGC-1α/TFAM通路改善线粒体功能减轻肝细胞性黄疸的机制研究
基金项目(Foundation): 省部共建中医湿证国家重点实验室开放课题项目(编号:SZ2021KF14)
邮箱(Email): hesongqijz@126.com;
DOI: 10.13412/j.cnki.zyyl.2026.02.002
摘要:

目的:研究茵陈五苓散对胆红素联合丙磺舒诱导的HepaRG黄疸细胞模型的影响,探讨其退黄作用机制。方法:将HepaRG细胞随机分为正常对照血清组、3.42、6.84、13.68 g/kg茵陈五苓散10%含药血清组、0.10 g/kg熊去氧胆酸10%含药血清组、6.84 g/kg茵陈五苓散含药血清+10μmol/L多索吗啡组、6.84 g/kg茵陈五苓散含药血清+0.095 mmol/L阿卡地新组,CCK-8法检测细胞活力;除正常对照血清组外,均采用胆红素联合丙磺舒构建HepaRG黄疸细胞模型,加入相应药物或含药血清,检测细胞内总胆红素(TBIL)、间接胆红素(IBIL)含量和细胞外直接胆红素(DBIL)含量;检测细胞活性氧(ROS)、线粒体膜电位水平和三磷酸腺苷含量(ATP);实时荧光定量聚合酶链式反应(Real-time qPCR)和蛋白免疫印迹法(Western blot)分别检测腺苷活化蛋白激酶(Ampk)/过氧化物酶体增殖物激活受体γ辅激活因子1α(Pgc1α)/线粒体转录因子A(Tfam)通路相关靶点mRNA和蛋白表达。结果:与正常对照血清组相比,3.42、6.84、13.68 g/kg茵陈五苓散10%含药血清组及熊去氧胆酸10%含药血清组对细胞活力无明显影响(P>0.05);与正常对照血清组相比,模型对照组细胞TBIL、IBIL含量和ROS水平显著升高(P<0.01),Pgc1α、Tfam的mRNA表达显著下调(P<0.01),p-AMPK、PGC-1α、TFAM蛋白表达明显下调(P<0.05),线粒体膜电位和ATP含量显著降低(P<0.01);与模型对照组相比,3.42、6.84、13.68 g/kg茵陈五苓散10%含药血清组及熊去氧胆酸10%含药血清组细胞内TBIL、IBIL含量显著降低(P<0.01),细胞外DBIL含量显著升高(P<0.01),6.84 g/kg茵陈五苓散10%含药血清组Pgc1α和Tfam的mRNA表达显著上调(P<0.01),p-AMPK、PGC-1α、TFAM蛋白表达明显上调(P<0.05),ROS水平显著降低(P<0.01),线粒体膜电位水平、ATP含量显著升高(P<0.01);与6.84 g/kg茵陈五苓散10%含药血清组相比,6.84 g/kg茵陈五苓散含药血清+10μmol/L多索吗啡组Pgc1α、Tfam的mRNA表达显著下调(P<0.01),p-AMPK、PGC-1α、TFAM蛋白表达明显下调(P<0.05),ROS水平显著升高(P<0.01),线粒体膜电位水平、ATP含量显著降低(P<0.01)。结论:茵陈五苓散通过激活AMPK/PGC-1α/TFAM通路,改善HepaRG黄疸细胞模型中线粒体膜电位,降低ROS水平,提高ATP含量,进而发挥退黄作用。

Abstract:

Objective:To investigate the effects of Yinchen Wuling(茵陈五苓) Powder on the HepaRG cell model of jaundice induced by bilirubin and probenecid and explore the underlying anti-jaundice mechanism. Methods:HepaRG cells were randomly allocated into the following groups: normal control, Yinchen Wuling Powder-containing serum(3.42,6.84,and 13.68 g/kg),0.10 g/kg ursodeoxycholic acid-containing serum, 6.84 g/kg Yinchen Wuling Powder-containing serum, 6.84 g/kg Yinchen Wuling Powder-containing serum+10 μmol/L dorsomorphin, and 6.84 g/kg Yinchen Wuling Powder-containing serum+0.095 mmol/L AICAR groups. Cell viability was assessed by the CCK-8 assay. Except the normal control group, other groups of HepaRG cells were treated with bilirubin combined with probenecid for the modeling of jaundice. The cells were then exposed to different doses of corresponding drugs or drug-containing serum, followed by measurement of intracellular total bilirubin(TBIL) and indirect bilirubin(IBIL),as well as extracellular direct bilirubin(DBIL). Reactive oxygen species(ROS),mitochondrial membrane potential, and adenosine triphosphate(ATP) levels were assessed. The protein and mRNA levels of related targets in the adenosine monophosphate-activated protein kinase(AMPK)/peroxisome proliferator-activated receptor λ coactivator 1α(PGC-1α)/transcription factor A,mitochondrial(TFAM) signaling pathway were analyzed by Western blot and real-time quantitative PCR,respectively. Results:No significant differences were observed in cell viability between the normal control and various Yinchen Wuling Powder-containing serum(3.42,6.84,and 13.68 g/kg) or 0.10 g/kg ursodeoxycholic acid-containing serum groups(P>0.05). Compared with the normal control group, the model control group exhibited elevated intracellular TBIL and IBIL levels(P<0.01),down-regulated mRNA levels of Pgc1α and Tfam(P<0.01),down-regulated protein levels of phosphorylated AMPK(p-AMPK),PGC-1α,and TFAM(P<0.05),raised ROS level(P<0.01),reduced mitochondrial membrane potential(P<0.01),and decreased ATP content(P<0.01). Compared with the model control group, all Yinchen Wuling Powder(3.42,6.84,and 13.68 g/kg) groups and 0.10 g/kg ursodeoxycholic acid group exhibited declined intracellular TBIL and IBIL levels(P<0.01) and elevated extracellular DBIL level(P<0.01). Compared with the model control group, the 6.84 g/kg Yinchen Wuling Powder-containing serum group showed up-regulated mRNA levels of Pgc1α and Tfam(P<0.01),up-regulated protein levels of p-AMPK,PGC-1α,and TFAM(P<0.05),lowered ROS level(P<0.01),enhanced mitochondrial membrane potential(P<0.01),and increased ATP content(P<0.01). Compared with the 6.84 g/kg Yinchen Wuling Powder-containing serum group, the addition of 10 μmol/L dorsomorphin down-regulated the mRNA levels of Pgc1α and Tfam(P<0.01) and the protein levels of p-AMPK,PGC-1α,and TFAM(P<0.05),raised the ROS level(P<0.01),decreased the mitochondrial membrane potential(P<0.01),and reduced the ATP content(P<0.01). In contrast, no significant differences were observed in these parameters between the 6.84 g/kg Yinchen Wuling Powder-containing serum group and the 6.84 g/kg Yinchen Wuling Powder-containing serum+0.095 mmol/L AICAR group. Conclusion:Yinchen Wuling Powder exerts its anti-jaundice effect by activating the AMPK/PGC-1α/TFAM signaling pathway, thereby improving mitochondrial membrane potential, reducing the ROS level, and increasing the ATP content in the HepaRG cell model of jaundice.

参考文献

[1]魏向东,肖白君,丁喜英,等.《金匮要略》黄疸病之证治探赜[J].时珍国医国药,2024,35(9):2222-2225.

[2]Tellez-Zarate M,Meza-Hernandez J,Jimenez-Fuentes E.Neuroganglioma in the posterior mediastinum:an incidental discovery[J].J Surg Case Rep,2024,2024(3):rjae156.

[3]QIN Y J,GAO T,ZHOU X N,et al.Autoimmune hepatitis-primary biliary cholangitis overlap syndrome complicated by various autoimmune diseases:A case report[J].World J Clin Cases,2024,12(6):1174-1181.

[4]Kloub M N,Elfert K,Elnajjar A,et al.Obstructive Jaundice Secondary to Hepatic Hilar Tuberculosis Without Pulmonary Involvement.Eur J Case Rep Intern Med,2024,11(2):004277.

[5]LIU J,SHEN T,LI L,et al.A systemic lupus erythematosus patient with persistent elevated conjugated bilirubin as the initial symptom:A case report[J].Medicine (Baltimore),2024,103(6):e36999.

[6]LI J,ZHUO S,CHEN B,et al.Clinical efficacy of laparoscopic modified loop cholecystojejunostomy for the treatment of malignant obstructive jaundice[J].J Int Med Res,2020,48(2):300060519866285.

[7]YOU L P,WANG K X,LIN J C,et al.Yin-chen Wu-ling powder alleviate cholestatic liver disease:Network pharmacological analysis and experimental validation[J].Gene,2023,851:146973.

[8]杨雯,王敏,唐金模.胆汁淤积性肝病的中医诊治概况[J].中西医结合肝病杂志,2023,33(5):452-455.

[9]谭艳,陈聪,周聪,等.历代医家对黄疸病的认识[J].中国中医急症,2021,30(1):149-51,55.

[10]林基伟,韩志毅,欧金龙,等.清代名医王旭高辨证论治黄疸经验探讨[J].中国民间疗法,2023,31(23):7-9.

[11]李若梦,吴凝,赵琳琳,等.茵陈五苓散对高脂血症大鼠的调脂及抗凝血作用[J].中国老年学杂志,2016,36(2):259-261.

[12]Nair A,Morsy M A,Jacob S.Dose translation between laboratory animals and human in preclinical and clinical phases of drug development[J].Drug Dev Res,2018,79(8):373-382.

[13]饶志,张帆,张国强,等.应用优化高胆红素HepaRG细胞模型筛选茵栀黄含药血清中的潜在药效物质[J].药学学报,2019,54(4):645-652.

[14]姜德友,韩洁茹.黄疸病源流考[J].中华中医药学刊,2009,27(1):16-18.

[15]李泽鹏,池晓玲,左俊岭,等.黄疸治法探析[J].新中医,2013,45(3):182-183.

[16]林佳媛,马国.胆红素代谢及其调节的研究进展[J].复旦学报(医学版),2014,41(3):405-411.

[17]李秋红,邵勇.胆红素在肝脏的代谢及调节机制研究进展[J].肝脏,2012,17(1):56-59.

[18]姚光弼.胆红素代谢[J].肝脏,2004,(1):44-46.

[19]Yokoyama Y,Sasaki Y,Terasaki N,et al.Comparison of Drug Metabolism and Its Related Hepatotoxic Effects in HepaRG,Cryopreserved Human Hepatocytes,and HepG2 Cell Cultures[J].Biol Pharm Bull,2018,41(5):722-732.

[20]Nunnari J,Suomalainen A.Mitochondria:in sickness and in health[J].Cell,2012,148(6):1145-59.

[21]Hsu C C,Peng D,Cai Z,et al.AMPK signaling and its targeting in cancer progression and treatment[J].Semin Cancer Biol,2022,85:52-68.

[22]Herzig S,Shaw R J.AMPK:guardian of metabolism and mitochondrial homeostasis[J].Nat Rev Mol Cell Biol,2018,19(2):121-135.

[23]ZHAN Y,WU G,FAN X,et al.YAP upregulates AMPKα1 to induce cancer cell senescence[J].Int J Biochem Cell Biol,2024,170:106559.

[24]HE X,YUAN D.A review regarding the article 'Targeting inflammatory signaling pathways with SGLT2 inhibitors:Insights into cardiovascular health and cardiac cell improvement'[J].Curr Probl Cardiol,2024,49(6):102563.

[25]Jäger S,Handschin C,St-Pierre J,et al.AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha[J].Proc Natl Acad Sci U S A,2007,104(29):12017-12022.

[26]ZHU Z,WANG X,SONG Z,et al.Photobiomodulation promotes repair following spinal cord injury by restoring neuronal mitochondrial bioenergetics via AMPK/PGC-1α/TFAM pathway[J].Front Pharmacol,2022,13:991421.

[27]JIA Z Q,LI G,ZHANG Z Y,et al.Time representation of mitochondrial morphology and function after acute spinal cord injury[J].Neural Regen Res,2016,11(1):137-143.

[28]Ay M,Charli A,Langley M,et al.Mito-metformin protects against mitochondrial dysfunction and dopaminergic neuronal degeneration by activating upstream PKD1 signaling in cell culture and MitoPark animal models of Parkinson's disease[J].Front Neurosci,2024,18:1356703.

[29]万璐,钱宇池,倪文静,等.利格列汀通过激活AMPK//PGC-1α/TFAM通路改善糖尿病肾脏疾病线粒体生物合成[J].南方医科大学学报,2023,43(12):2053-2060.

基本信息:

DOI:10.13412/j.cnki.zyyl.2026.02.002

中图分类号:R285

引用信息:

[1]钟冰莲,王一钦,江稳滔,等.茵陈五苓散调控AMPK/PGC-1α/TFAM通路改善线粒体功能减轻肝细胞性黄疸的机制研究[J].中药药理与临床,2026,42(02):2-9.DOI:10.13412/j.cnki.zyyl.2026.02.002.

基金信息:

省部共建中医湿证国家重点实验室开放课题项目(编号:SZ2021KF14)

发布时间:

2026-02-15

出版时间:

2026-02-15

检 索 高级检索